1. | longswin | |
2. | debgptl | |
3. | STOCKnLAW | |
4. | deathswrestler | |
5. | deadRinger |
1. | longswin | |
2. | debgptl | |
3. | STOCKnLAW | |
4. | deathswrestler | |
5. | deadRinger |
1. | STOCKnLAW 10/23/2018 AcelRx Provides Updated Comments Following Positive FDA Advisory Committee Meeting |
2. | STOCKnLAW 10/02/2017 Demand AH continues. Only 7 trading days til FDA decision, or earlier?!. |
3. | STOCKnLAW 10/10/2018 ACRX$3.73 (40.8%) |
4. | deathswrestler 06/27/2018 Announces that the European Commission has approved DZUVEO |
5. | STOCKnLAW 07/16/2018 Why You Shouldn't Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock |
6. | deadRinger 10/02/2017 Cool off before the 12th then jump? |
7. | longswin 10/15/2018 Acelrx (ACRX) Stock Is Firing on All Cylinders; Cantor Boosts Price Target |
8. | longswin 04/11/2018 Announces publication of a report commissioned by AcelRx analyzing the economic burden associated with admin… |
9. | deathswrestler 04/18/2018 Announces the publication of an analysis of the pharmacokinetic characteristics of sublingually administered… |
10. | longswin 04/16/2018 News out here - AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018 |